Scienture Holdings, Inc.

Scienture Holdings, Inc.

SCNX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$3.61M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Scienture Holdings, Inc.Scienture Holdings, Inc.-0.1-2648446%--11.7
$6.00

Target Price by Analysts

163.4% upsideScienture Holdings Target Price DetailsTarget Price
$1.01

Current Fair Value

55.5% downside

Overvalued by 55.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$3.61 Million
Enterprise Value$22.98 Million
Earnings per Share$-67.5
Beta4.08
Outstanding Shares1,584,633

Return

Return on Equity2648446.31%ROE
Return on Assets-115942.23%
Return on Invested Capital-5728808.93%

Valuation & Multiples

P/E Ratio-0.06P/E Ratio
PEG0.02PEG
Price to Sales0.01Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue0.05
Enterprise Value to EBIT0
Enterprise Value to Net Income-1
Total Debt to Enterprise0.86
Debt to Equity-11.7Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 18, 2026
EPS Estimate
-$1.57
Consensus analyst estimate
Revenue Estimate
$1.22 M
Consensus analyst estimate

Next Earnings Call

Expected Date
March 29, 2027
EPS Estimate
-$0.37
Consensus analyst estimate
Revenue Estimate
$1.46 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %3.19%▼ 1.93%
Total Invested$329,719▼ 53.50%
Investors Holding8▼ 8.00%

About Trxade Group Inc

9 employees
CEO: Shankar Hariharan

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops ...